1. Introduction {#sec1}
===============

Deoxyribonucleic acid (DNA) methylation is a biochemical process catalyzed by DNA methyltransferase enzymes to covalently add a methyl group at the 5′ position of cytosine DNA nucleotides, creating 5-methylcytosine in CpG dinucleotides concentrated in gene promoters \[[@B1]\]. The CpG dinucleotides in gene promoters are not generally methylated; thus methylation at these sites is associated with changes in gene expression. Hypermethylation represses transcription, thereby reducing gene expression, while hypomethylation is associated with transcriptional activation of the affected genes \[[@B2], [@B3]\]. DNA methylation is the most characterized of the epigenetic processes, which also include histone modification, chromatin remodeling, and noncoding RNAs. Epigenetics, defined as mechanisms that affect gene transcription and/or expression in the absence of alterations to the DNA sequence, provides a plausible link between genetic and environmental determinants of health status. Current studies have shown congruence of epigenetic loci and gene polymorphisms in diseases \[[@B4]--[@B7]\]. In type 2 diabetes, for example, 19 single nucleotide polymorphisms (SNPs) associated with the disease introduced or removed potential sites for DNA methylation \[[@B7]\]. Furthermore, the genetic-epigenetic-environment link has been demonstrated in a report that showed an association between the nuclear-encoded gene, NADH dehydrogenase \[ubiquinone\] 1 beta subcomplex subunit 6 (NDUFB6) polymorphism, DNA methylation, age, and the expression of NDUFB6 in human skeletal muscle \[[@B4]\].

Estimates from the International Diabetes Federation (IDF) suggest that the population of people with diabetes is growing relatively faster in Africa compared to anywhere else \[[@B8]\]. Emerging evidence suggests that this process is not entirely accounted for by the traditional drivers of the diabetes epidemic. In mixed ancestry South Africans, for instance, who are largely overweight or obese and at high risk of diabetes \[[@B9]\], the distribution of traditional risk factors for diabetes is not appreciably different between individuals with diabetes and those without diabetes, while the accelerated deterioration of glucose tolerance status over time is not explained by the known powerful determinants of diabetes occurrence \[[@B10]\]. In this context, the contribution of emerging risk factors for diabetes including epigenetic changes has been postulated \[[@B11]\] but remains largely uninvestigated. It, therefore, became our primary aim to investigate nontraditional context specific diabetes risk factors and pathophysiological pathways underlying the excess risk of diabetes in this population. Herein, we report the South African mixed ancestry population\'s specific differentially methylated sites and metabolic pathways affected by DNA methylation in this population.

2. Subjects {#sec2}
===========

Participants were members of a cohort study conducted in Ward 009, Cape Town, South Africa. The city of Cape Town defines Ward 009 as a mixed ancestry township formed in the late 1950s. According to the 2011 population census, its population stands at approximately 29,301 with an average household size of 4.84 individuals. The population is predominantly of mixed ancestry or coloured (76%) followed by black Africans (18.5%) and Caucasian and Asians who make only 1.5%. Most of the residents in this community have lived there for more than five years, while others have been there for their entire lives. The socioeconomic condition of the people is average with 37% of households having a monthly income of ZAR3, 200 or less. The recruitment of the Ward 009 cohort was initiated in April 2014, from which 3 individuals with screen detected diabetes, 3 individuals with prediabetes, and 3 individuals with normoglycaemia who were age-, gender-, body mass index- (BMI-), duration of residency-matched were selected for the current study. All participants were females.

3. Materials and Methods {#sec3}
========================

3.1. Ethical Approval of the Study {#sec3.1}
----------------------------------

This investigation is based on the Bellville South (Ward 009) cohort from Cape Town that has been approved by the Research Ethics Committees of the Cape Peninsula University of Technology and Stellenbosch University (resp., NHREC: REC-230 408-014 and N14/01/003). The study was conducted according to the Code of Ethics of the World Medical Association (Declaration of Helsinki). All participants signed written informed consent after all the procedures had been fully explained in the language of their choice.

3.2. Study Procedures {#sec3.2}
---------------------

All participants received a standardized interview, blood pressure, and anthropometric measurements. Participants with no history of doctor-diagnosed diabetes mellitus underwent a 75 g oral glucose tolerance test (OGTT) as recommended by WHO \[[@B12]\]. Further, the following biochemical parameters were analyzed at an ISO 15189 accredited pathology practice (PathCare, Reference Laboratory, Cape Town, South Africa): plasma glucose, serum insulin, serum creatinine, total cholesterol (TC), high density lipoprotein cholesterol (HDL-c), triglycerides (TG), low density lipoprotein cholesterol (LDL), C-reactive protein (CRP), *γ*-glutamyl transferase (GGT), AST, ALT, and glycated haemoglobin (HbA1c), certified by National Glycohemoglobin Standardization Program (NGSP). Full blood count was also assessed on all participants. In addition, an EDTA blood sample was collected and stored at −20 degrees for DNA extraction and analysis.

3.3. Genome-Wide DNA Methylation {#sec3.3}
--------------------------------

Genomic DNA was extracted from peripheral blood using the Wizard® Genomic DNA Purification Kit (Promega, Madison, WI, USA) according to the manufacturer\'s instructions. Briefly, white blood cells were lysed; thereafter, cellular proteins were removed by salt precipitation, and high molecular weight genomic DNA left in solution was then concentrated and desalted by isopropanol precipitation. At least 2 *μ*g of DNA (concentrations ranging between 70 ng/*μ*L and 130 ng/*μ*L) with A260/A280 and A260/A230 ratios ≥ 1.8 was shipped frozen on dry ice, as instructed by Arraystar Inc. (Rockville, MD, USA). Methylated DNA immunoprecipitation (MeDIP) was performed by Arraystar Inc. (Rockville, MD, USA) according to Down et al. \[[@B13]\] with minor modifications as follows.

3.4. Sequencing Library Preparation {#sec3.4}
-----------------------------------

For MeDIP, genomic DNA was sonicated to \~200--900 bp with a Bioruptor sonicator (Diagenode, Denville, NJ, USA). Thereafter, 800 ng of sonicated DNA was end-repaired, A-tailed, and ligated to single-end adapters following the standard Illumina genomic DNA protocol. After agarose size selection to remove unligated adapters, the adaptor-ligated DNA was used for immunoprecipitation using a human monoclonal anti-5-methylcytosine antibody (Diagenode). For this, DNA was heat-denatured at 94°C for 10 min, rapidly cooled on ice, and immunoprecipitated with 1 *μ*L of primary antibody overnight at 4°C with rocking agitation in 400 *μ*L of immunoprecipitation buffer (0.5% BSA in PBS). To recover the immunoprecipitated DNA fragments, 100 *μ*L of protein G magnetic beads (Life Technologies, Carlsbad, CA, USA) was added and incubated for additional 2 hours at 4°C with agitation. After immunoprecipitation, a total of five immunoprecipitation washes were performed with ice-cold immunoprecipitation buffer. A nonspecific human IgG immunoprecipitation was performed in parallel to methyl DNA immunoprecipitation as a negative control. Washed beads were resuspended in TE buffer with 0.25% SDS and 0.25 mg/mL proteinase K for 2 hours at 65°C and then allowed to cool down to room temperature. MeDIP and supernatant DNA were purified using Qiagen MinElute columns and eluted in 16 *μ*L EB (Qiagen, Germantown, MD, USA). Fourteen cycles of PCR were performed on 5 *μ*L of the immunoprecipitated DNA using the single-end Illumina PCR primers. The resulting reactions were purified with Qiagen MinElute columns, after which a final size selection (300--1,000 bp) was performed by electrophoresis in 2% agarose. Libraries were quality controlled with the Agilent 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA). An aliquot of each library was diluted in EB (Qiagen) to 5 ng/*μ*L and 1 *μ*L was used in real-time PCR reactions to confirm the enrichment for methylated region. The enrichment of DNA immunoprecipitation was analyzed by qPCR using specific methylated sites at H19 locus and nonmethylated sites at GAPDH.

3.5. Sequencing {#sec3.5}
---------------

The library was denatured with 0.1 M NaOH to generate single-stranded DNA molecules and loaded onto channels of the flow cell at 8 pM concentration, amplified*in situ*using TruSeq Rapid SR Cluster Kit (Illumina, San Diego, CA, USA). Sequencing was carried out by running 100 cycles on Illumina HiSeq 2000 according to the manufacturer\'s instructions. The Agilent 2100 Bioanalyzer was used for accurate assessment of the quality and concentration of the sequencing library, while the size and concentration of each sample were determined after sequencing library preparation.

3.6. Data Analysis {#sec3.6}
------------------

After the sequencing platform generated the sequencing images, the stages of image analysis and base calling were performed using Off-Line Basecaller software (OLB V1.8). After passing Solexa CHASTITY quality filter, the clean reads were aligned to the human genome (UCSC HG19) using BOWTIE software (V2.1.0). MeDIP peaks were identified by MACS2 and MAnorm identified DMRs. Statistically significant MeDIP-enriched regions (peaks) detected by MACS2 were identified by comparison to a Poisson background model, using a*q*-value threshold of 10^−2^. The peaks in samples were annotated by the nearest gene (the nearest TSS to the canter of peak region) using the newest UCSC RefSeq database. Peaks were divided into 3 classes on the basis of their distances to UCSC RefSeq genes:*Promoter peaks*: promoters were defined as 2000 bp upstream and downstream from the transcription start site (TSS). Peaks whose centers were located in these promoter regions were defined as promoter peaks.*Gene body peaks*: the gene body region was defined as +2000 bp downstream of the transcription start site (TSS) to the transcription termination site (TTS).*Intergenic peaks*: intergenic regions were defined as the other genomic regions not included in the above 2 regions. Peaks whose centers were located in these intergenic regions were defined as intergenic peaks. MAnorm was used to calculate differentially methylated regions with statistical significance.

3.7. Solexa CHASTITY Quality Filter {#sec3.7}
-----------------------------------

Individual bases generated from original image files have quality scores, which reflect the probability whether base calling is correct or not. The score is calculated by CHASTITY Formula. The CHASTITY (C) of each base in the short reads is determined by the intensity of four colours (*I* ~*A*~,*I* ~*C*~,*I* ~*G*~, and*I* ~*T*~ here), and the formula means "the ratio of the highest (*I* ~*C*~ here) of the four (base type) intensities to the sum of highest two (*I* ~*C*~ and*I* ~*G*~ here)." The CHASTITY (C) should be no less than 0.6 in the first 25 bases.

3.8. Gene Ontology (GO) Analysis {#sec3.8}
--------------------------------

The Gene Ontology project provides a controlled vocabulary to describe gene and gene product attributes in any organism (<http://www.geneontology.org/>). The ontology covers three domains: biological process, cellular component, and molecular function. Fisher\'s exact test was used to find if there was more overlap between the DE list and the GO annotation list than would be expected by chance. The *P* value denotes the significance of GO terms enrichment in the DE genes. The lower the *P* value, the more significant the GO Term; a *P* value ≤ 0.05 was considered significant.

3.9. Pathway Analysis {#sec3.9}
---------------------

Pathway analysis is a functional analysis mapping of genes to KEGG pathways. The *P* value (EASE score, Fisher\'s*P* value, or hypergeometric*P* value) denotes the significance of the pathway correlated to the conditions. The lower the *P* value is, the more significant the pathway is; a *P* value ≤ 0.05 was considered significant.

4. Results {#sec4}
==========

4.1. General Characteristics of Participants {#sec4.1}
--------------------------------------------

The general characteristics of the nine female participants are presented in [Table 1](#tab1){ref-type="table"} for each participant and further summarized across subgroups defined by the glucose tolerance status. All participants had reported no menstrual periods for 6 months or more prior to taking part in this study. As expected from the study design, age and BMI were mostly similar across subgroups, with all participants being obese. Hip circumferences were mostly similar across subgroups, while waist circumference and waist-to-hip ratio decreased with improved glucose tolerance. Blood pressure levels were lowest in normotolerant subjects and highest in those with prediabetes. The lipid profile and indicators of glycaemia improved with improving glucose tolerance status, while fasting insulin levels decreased accordingly ([Table 1](#tab1){ref-type="table"}).

4.2. Differentially Methylated Regions {#sec4.2}
--------------------------------------

A total of 450,142 statistically significant MeDIP-enriched regions (peaks) were identified in all the samples. As expected, the promoter region \[TSS − 2000 bp; TSS + 2000 bp\] showed the least number of peaks, compared to the gene body and intergenic regions, in all groups. MAnorm was then used to calculate the statistical significance of differentially methylated regions (DMRs) within gene promoters. Subjects with diabetes showed the highest number of DMRs and these are summarized in [Figure 1](#fig1){ref-type="fig"}. Generally, more than 80% of DMRs in subjects with diabetes were hypermethylated when compared to those with prediabetes or normoglycaemia, while no differences were observed between subjects with prediabetes or normoglycaemia ([Figure 1](#fig1){ref-type="fig"}). Supplementary Tables 1 to 6 in Supplementary Material available online at <http://dx.doi.org/10.1155/2016/3172093> show the DMRs in subjects with diabetes, subjects with prediabetes, and controls. To summarize these data, we grouped the DMRs according to chromosomal location and this is shown in [Figure 2](#fig2){ref-type="fig"}. Compared to controls and subjects with prediabetes, hypermethylated DMRs in subjects with diabetes were more common in chromosomes, 3, 6, 11, 13, and 17, while in chromosome one, there were more hypomethylated DMRs ([Figure 2](#fig2){ref-type="fig"}). No hypomethylated DMRs were present in chromosome 13 in subjects with diabetes or prediabetes when compared with each other or when those with prediabetes were compared to controls ([Figure 2](#fig2){ref-type="fig"}).

4.3. Pathway Analysis {#sec4.3}
---------------------

We first performed Gene Ontology (GO) classification to retrieve the biological process, cellular process, and molecular function of the DMRs and these are presented in Supplementary Tables 2--24, while [Figure 3](#fig3){ref-type="fig"} shows biological processes in the top 10 enrichment scores for DMRs in subjects with diabetes or prediabetes. As shown in [Figure 3](#fig3){ref-type="fig"}, these hypermethylated DMRs in subjects with diabetes or prediabetes were widely associated with cell surface receptor signaling and inflammatory pathways. In addition, glucose transport, WNT signaling, muscle development, pancreas development genes, and insulin signaling pathway were associated with hypermethylation in subjects with diabetes or prediabetes (Supplementary Tables 7--12). Although the I-kappaB kinase/NF-kappaB cascade was associated with hypomethylated DMRs in subjects with diabetes and hypermethylated DMRs in subjects with prediabetes, the genes associated with these pathways were different in each group. For example, in subjects with prediabetes, the hypermethylated genes were CHUK, TRIM38, PLK2, TNFRSF19, and ZMYND11, while in subjects with diabetes they were BCL3, IL23A, F2RL1, S100A12, TNFRSF10B, NEK6, RNF31, SLC35B2, and IRAK1BP1. Pathway analysis based on the functional analysis mapping of genes to KEGG pathways also showed an association with inflammatory pathways ([Table 2](#tab2){ref-type="table"}). The linoleic acid metabolism and arachidonic acid metabolism pathways were progressively hypomethylated from prediabetes to diabetes. On the other hand, the hypertrophic cardiomyopathy (HCM) pathway was associated with hypermethylated DMRs in subjects with diabetes when compared to either controls or subjects with prediabetes.

5. Discussion {#sec5}
=============

Emerging data supports the role of epigenetic mechanisms in the development of diabetes; however, to date, genome-wide DNA methylation profiling has not involved subjects with prediabetes or diabetes from sub-Saharan Africa or Africa in general. In this preliminary genome-wide DNA methylation analysis of individuals with prediabetes or diabetes from South Africa, we provide DMRs data and their biological pathways that appear to be affected in subjects with diabetes or prediabetes, as well as those that appear to show a trend from the prediabetes state to diabetes. For instance, the linoleic acid metabolism and arachidonic acid metabolism pathways were associated with hypomethylated DMRs in subjects with prediabetes versus controls and in those with diabetes versus those with prediabetes, suggesting that the hypomethylation of these genes is likely to be an early process that occurs before the onset of overt diabetes. Our data also shows that genes related to the immune system, signal transduction, glucose transport, and pancreas development are hypermethylated in subjects with prediabetes or diabetes. When they are investigated further, these DMRs may be potential biomarkers of disease occurrence/progression and also could suggest possible targets for the development of new treatments.

Whole epigenetic profiling in individuals with type 2 diabetes is relatively in its infancy with the first study reported in 2012. The study was conducted using pancreatic islets of 5 individuals with type 2 diabetes and identified 276 DMRs, where 96% of the 254 DMRs located in the promoter region were hypomethylated \[[@B14]\]. The DMRs were associated with beta-cell function, cell death, and adaptation to metabolic stress. Similar DMRs (71) to Volkmar et al. \[[@B14]\] have recently been reported in a study, where they were associated with pathways in cancer, axon guidance (SEMA4A and SEMA5B), MAPK signaling (CACNA1H) focal adhesion (ITGB4), ECM-receptor interaction (AGRN and TGB4), and actin cytoskeleton (TGB4) \[[@B7]\]. Furthermore, the study showed an increased accumulation of the DMRs in chromosomes 1 and 2, while in chromosome 19, DMRs were lessened \[[@B7]\]. In the current study, we found a total of 1415 DMRs in the promoter regions of subjects with diabetes when compared to control subjects and 81.7% of these were hypermethylated. Similar to Dayeh et al.\'s \[[@B7]\] report, the DMRs were mostly accumulated in chromosomes 1 and 2 but were least in chromosome 21 in subjects with diabetes compared to controls in our study. We also observed similar finding between subjects with prediabetes and controls showing higher accumulation in chromosomes 1 and 2, while chromosomes 13, 16, 18, 20, 21, and 22 had less than 10 DMRs. A longitudinal study that investigated hypomethylated DMRs showed that progression from normoglycaemia to a worse glucose tolerance state was associated with early differential methylation prior to disease manifestation \[[@B15]\]. The authors analyzed methylation levels of candidate DMRs identified by whole epigenetic profiling in 62 subjects with impaired glucose metabolism and 64 controls who maintained a normal glucose tolerance status during follow-up and demonstrated significantly lower percent of methylation before the appearance of the disease in those that progressed \[[@B15]\]. Similarly, we have also observed common DMRs as well as common pathways in prediabetes and diabetes individuals\' inflammatory genes including the lipid metabolism pathway, which appeared to be progressively modified from prediabetes state to diabetes. We observed that the arachidonic acid (AA) pathway was hypomethylated and appeared to be modified in prediabetic and diabetic states; however, different isoforms of the genes were involved in each glycaemic state. For example, in subjects with prediabetes versus controls, cytochrome P450, family 4, subfamily F, polypeptide 3 (CYP4F3), CYP4F8, Phospholipase A2, group IIC (PLA2G2C), and PLA2G4E were differentially methylated, while in subjects with diabetes versus prediabetes, CYP2E1 and PLA2G12A were involved.

Lipids are important components of all mammalian cells and have a variety of biological functions, including serving as energy reservoirs and mediators of inflammation known as oxylipins. Oxylipins result from the oxygenation of PUFAs by three types of enzymes, cyclooxygenases, lipoxygenases, and cytochrome P \[[@B16]\]. The type of PUFA oxidized and enzyme involved determine the production of oxylipins. The arachidonic acid (AA) generates most of the inflammatory molecules involved in cell signaling cascades and is a precursor of eicosanoids. Eicosanoids include prostaglandins (PGAs), leukotrienes (LTs), and thromboxanes (TXAs) and their role is dependent on the type of fatty acid from which they are derived \[[@B17]\]. In this regard, we also observed differentially methylated signals of cytochrome P450 and Phospholipase A2 (PLA2). Inflammatory activation of the PLA2 enzyme promotes the release of AA from cell membranes phospholipids, which in turn is metabolized by cyclooxygenases (COX), yielding eicosanoids \[[@B17]\]. Taken together, the epigenetic modifications of oxylipins indirectly represent a chronic inflammatory pathway involvement in diabetes development. Because fatty acids are derived from the diet in the form of linoleic acid, followed by desaturation and elongation into specific fatty acids, the elucidation of lipid pathway epigenetics may contribute to the formulation of treatment and prevention strategies. For instance, supplement studies using AA, EPA, and/or ALA have demonstrated an effect on the production of eicosanoids and inflammatory markers. In a study comprising healthy males, 1.5 g of AA increased PGE2 and leukotriene LTB4 \[[@B18]\], while supplementation with fish oil containing EPA and DHA decreased the generation of TNF*α* and IL-1 by 70% and 78%, respectively \[[@B19]\]. Moreover, epigenetic changes are reversible to an extent that in some neurological diseases and cancers epigenetic drugs have been proposed or are currently being used \[[@B20], [@B21]\]. In cancer, for instance, methylation inhibiting drugs include cytidine analogs such as 5-azacitidine \[[@B22]\] and zebularine \[[@B23]\]. In view of the above, it is clear that epigenetics do offer tremendous opportunities for treatment and management of diseases.

Considering the current published literature on the epigenetics of type 2 diabetes globally, it is encouraging to note that a few whole epigenomic studies have been conducted in populations from Africa. These include studies that investigated the effect of environment in Moroccans, Ethiopians, and Egyptians \[[@B24]--[@B26]\], severe bladder damage in Ghanaians \[[@B27]\], and exposure to famine in offspring from Gambia \[[@B28]\]. Epigenetic determinants have been shown to differ between populations. For example, in HapMap lymphoblastoid cell lines derived from individuals of European or African ancestry, population-specific cytosine modifications in samples derived from Yoruba people from Ibadan, Nigeria, and Caucasian residents of European ancestry from Utah were observed \[[@B29]\]. The differences between and within population groups have been linked to population-disease-specific single nucleotide polymorphisms (SNPs). In diabetes, for instance, 17 of the 40 type 2 diabetes candidate genes identified by genome-wide association studies (GWAS) were differentially methylated in pancreatic islets of subjects with diabetes \[[@B7]\]. Interestingly, in our study, KEGG pathway analysis identified hypomethylated DMRs in subjects with diabetes that were associated with African trypanosomiasis pathway. African trypanosomiasis is a sleeping sickness caused by*Trypanosoma* species from Africa, suggesting a population-specific selection of DNA methylation in this population with an African ancestry.

In this study, DNA methylation was investigated using whole genome MeDIP sequencing (MeDIP-Seq); though bisulfite sequencing is currently considered the gold standard for detecting DNA methylation, it does not distinguish between 5-methylcytosine (5mC) and 5-hydroxymethylcytosine (5hmC). While MeDIP-Seq obviates the need for bisulfite treatment of DNA, a limitation of the technique is the inability to detect individual differentially methylated CpG sites. A major limitation of this study is the lack of verification of regions using other sequencing-based DNA methylation profiling methods. However, a quantitative comparison of four sequencing-based DNA methylation methods including MeDIP-Seq demonstrated comparable methylation calls of all four methods but differences in CpG coverage, resolution, quantitative accuracy, efficiency, and cost \[[@B30]\]. Other limitations of the study include the one gender and small number of individuals investigated. The pancreatic *β*-cells are believed to be the ideal tissue for type 2 diabetes epigenetics. We made use of peripheral white blood cells and it has been shown that DNA methylation is different between blood cell types \[[@B31]\]; thus our findings should be interpreted with caution. While we carefully matched the participants, we take note that the smoking patterns were not similar between the groups. Therefore, it is likely that some of the DMRs observed are not necessarily due to diabetes or prediabetes but perhaps nicotine. Similarly, all participants were obese (BM1 \> 30 kg/m^2^); we cannot dismiss the fact that some DMRs are obesity related. Although the population investigated is from Africa, it is noteworthy to mention that this is a unique heterogeneous group, which is of mixed genetic origin with contributions from Europeans, South Asians, Indonesians, and a population genetically close to the isiXhosa sub-Saharan Bantu population \[[@B32]\]. Therefore we cannot rule out the possible role of genetic ancestral components in the methylation patterns observed. However, financial constraints and the technical complexity of generating ancestry informative markers, particularly for this South African population group, still remain a challenge.

In conclusion, our study provides basis for candidate methylation analysis in Africa. Considering that GWAS studies of diabetes involving populations from Africa are not available, we recommend methylation quantitative trail loci (meQTL) investigations coupled with ancestry informative markers to account for population stratification.

Supplementary Material {#supplementary-material-sec}
======================

###### 

Supplementary Tables 1 to 24 is an excel file. S1 to S6 shows DMRs within gene promoters in prediabetes vs controls (S1 and S2); diabetes vs controls (S3 and S4); diabetes vs prediabetes (S5 and S6). BP1 to BP6 depicts Gene Ontology (GO) classification of biological processes in diabetes vs controls (BP1 and BP2); diabetes vs prediabetes (BP3 and BP4); prediabetes vs controls (BP5 and BP6). CP1 to CP6 shows GO classification of cellular process in diabetes vs controls (CP1 and CP2); diabetes vs prediabetes (CP3 and CP4); prediabetes vs controls (CP5 and CP6). MF1 to MF6 shows GO classification of molecular function in diabetes vs controls (MF1 and MF2); diabetes vs prediabetes (MF3 and MF4); prediabetes vs controls (MF5 and MF6).
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![MeDIP-enriched regions (peaks) identified in all the samples. Total sites are the sum of the peak numbers for subjects with diabetes, subjects with prediabetes, and controls and include all the peaks that may be common/redundant across the conditions, as well as the peaks unique to each condition. Distributions of peaks in intergenic (I), gene body (GB), and promoter (P) regions are shown. Statistically significant MeDIP-enriched regions (peaks) were detected by MACS2 and identified by comparison to a Poisson background model, using a*q*-value threshold of 10^−2^. MAnorm was used to calculate differentially methylated regions with statistical significance. The differentially methylated regions located within gene promoters \[TSS − 2000 bp; TSS + 2000 bp\] are selected and provided. By peak number, there are more hypermethylated peaks in individuals with diabetes (82%) than in the control subjects.](IJE2016-3172093.001){#fig1}

![Accumulation of differentially methylated regions (DMRs) in chromosomes. (a) represents DMRs in diabetes versus controls, (b) represents DMRs in diabetes versus prediabetes, and (c) represents DMRs in prediabetes versus controls.](IJE2016-3172093.002){#fig2}

![GO analysis of the differentially methylated genes in diabetes, prediabetes, and controls. The bars plot shows the top ten enrichment score values of the significant enrichment terms.*X*-axis: GOID\'s enrichment score value; it equals −log 10(*P* value);*Y*-axis: GO category. (a) Hypomethylated diabetes versus controls. (b) Hypermethylated diabetes versus controls. (c) Hypomethylated diabetes versus prediabetes. (d) Hypermethylated diabetes versus prediabetes. (e) Hypomethylated prediabetes versus controls. (f) Hypermethylated prediabetes versus controls.](IJE2016-3172093.003){#fig3}

###### 

Characteristics of all participants.

                             Diabetes   Prediabetes   Controls                                                             
  -------------------------- ---------- ------------- ---------- ------- ------ ------ ------- ------ ------ ------ ------ -------
  Age, years                 62         52            52         55.3    52     50     55      52.3   62     52     52     55.3
  BMI, kg/m^2^               35.3       39.3          31.2       35.3    32.6   35.2   30.4    32.7   41.3   34.0   31.7   35.6
  WaistC, cm                 120        103           116        113     104    108    116     109    112    93     89     98
  HipC, cm                   118        124           113        118     108    119    129     118    127    124    106    119
  WHR                        1.02       0.83          1.02       0.96    0.96   0.91   0.90    0.93   0.88   0.75   0.84   0.82
  SBP, mmHg                  153        183           143        160     178    164    163     168    142    127    137    135
  DBP, mmHg                  78         130           61         90      109    101    78      96     72     75     92     80
  S-Creat., *μ*mol/L         45         75            35         52      69     47     52      56     62     58     50     57
  GGT, U/L^*∗*^              18         42            295        118     22     20     12      18     22     20     99     47
  ALT, U/L                   19         86            61         55      22     16     17      18     12     12     30     18
  AST, U/L                   24         45            50         40      21     18     18      19     21     16     30     22
  Smoking, yes/no            Yes        Yes           Yes                Yes    No     No             Yes    Yes    No      
  Cotinine, ng/mL^*∗*^       160        \>500         76.3       245.4   94     \<10   \<10    38     94.4   338    \<10   147.5
  TC, mmol/L                 6.0        6.0           8.3        6.8     4.9    4.1    5.5     4.8    3.6    5.2    4.7    4.5
  TG, mmol/L                 1.49       3.35          2.51       2.45    2.10   1.21   1.04    1.45   1.22   1.23   1.27   1.24
  HDL-C, mmol/L              1.09       1.1           1.87       1.35    1.09   1.17   1.42    1.23   1.35   1.08   1.42   1.28
  LDL-C, mmol/L              3.9        4.2           5.1        4.4     3.1    2.1    3.5     2.9    1.6    3.4    2.7    2.6
  FSI, mIU/L                 97.9       68.7          47.7       71.4    77.3   29.9   110.2   72.5   72.8   20.8   30.1   41.2
  FSI, mIU/L^*∗*^            20.7       21.2                     21.0    5.7    5.5    11.5    7.6    10.4   7.6    5.3    7.8
  HbA1c, %                   7.2        7.5           6.1        6.9     5.0    6.1    6.4     5.8    5.9    5.6    6.1    5.9
  HbA1c, mmol/mol            55.2       58.5          43.2       52.3    31.1   43.2   46.4    40.2   41.0   37.7   43.2   40.6
  FBG, mmol/L                9.0        8.1           7.8        8.3     4.7    6.2    6.1     5.7    5.4    2.8    5.8    4.7
  2-hour PG, mmol/L          16.4       13.8          5.9        12.0    7.8    10.3   9.4     9.2    7.4    5.0    6.1    6.2
  U-CRP, mg/L                3.2        10.4          5.3        6.3     5.2    15.6   21.6    14.1   23.4   8.2    5.9    12.5
  RBC, ×10^12^/L             4.56       5.07          4.37       4.67    4.86   4.42   4.88    4.72   3.75   4.42   4.82   4.33
  Platelet count, ×10^9^/L   284        217           369        290     238    286    305     276    281    152    256    230
  WCC, ×10^9^/L              8.6        10.0          7.8        8.8     7.1    8.0    8.9     8.0    6.0    8.3    4.6    6.3
  Hb, g/dL                   13.0       15.1          12.6       13.6    13.6   13.2   13.5    13.4   6.1    14.4   13.6   11.4
  Haematocrit, L/L           0.39       0.46          0.37       0.41    0.42   0.39   0.41    0.41   0.22   0.42   0.41   0.35
  MCV, fL                    85         90            85         87      86     89     83      86     57     95     86     79
  MCH, pg                    29         30            29         29      28     30     28      29     16     33     28     26
  MCHC, g/dL                 34         33            34         34      33     34     33      33     29     34     33     32
  RDW, %                     14.0       15.0          15.2       14.7    12.7   14.1   14.0    13.6   25.3   14.8   15.9   18.7
  Neutrophils, ×10^9^/L      5.6        7.2           4.6        5.8     4.5    4.5    5.4     4.8    2.8    5.7    2.9    3.8
  Lymphocytes, ×10^9^/L      2.3        2.0           2.4        2.2     2.1    3.0    2.8     2.6    2.3    1.9    1.4    1.9
  Monocytes, ×10^9^/L        0.50       0.30          0.40       0.40    0.30   0.30   0.30    0.30   0.72   0.46   0.20   0.46
  Eosinophils, ×10^9^/L      0.10       0.40          0.40       0.30    0.20   0.20   0.40    0.27   0.12   0.14   0.10   0.12
  Basophils, ×10^9^/L        0.01       0.01          0.10       0.04    0.01   0.01   0.01    0.01   0.06   0.04   0.01   0.04

2-hour PG, after 2-hour plasma glucose; 2-hour SI, after 2-hour serum insulin; ALT, alanine aminotransferase; AST, aspartate aminotransferase; DBP, diastolic blood pressure; FBG, fasting plasma glucose; FSI, fasting serum insulin; GGT, gamma glutamyl transpeptidase; Hb, haemoglobin; HDL-C, high density lipoprotein cholesterol; HipC, hip circumference; LDL-C, low density lipoprotein cholesterol; MCH, mean cell haemoglobin; MCHC, mean corpuscular haemoglobin concentration; MCV, mean cell volume; RBC, red blood cell count; RDW, red cell distribution width; S-Creat., serum creatinine; SBP, systolic blood pressure; TC, total cholesterol; TG, triglycerides; U-CRP, ultrasensitive C-reactive protein; WaistC, waist circumference; WCC, white cell count; WHR, waist-to-hip ratio.

*∗* refers to using the median instead of mean because, since the data is skewed for those parameters, the mean will give a wrong meaning.

###### 

KEGG analysis of top ten enrichment score (−log⁡10(*P* value)) values of the significant enrichment pathway.

  Pathway ID                                      Definition                                Fisher\'s *P* value   Enrichment score   Genes
  ----------------------------------------------- ----------------------------------------- --------------------- ------------------ ----------------------------
  *Hypomethylated diabetes*versus*control*                                                                                           
  hsa05143                                        African trypanosomiasis                   0.0073                2.133882           F2RL1//HPR//THOP1
  hsa05340                                        Primary immunodeficiency                  0.0086                2.064522           AIRE//CD8A//IGLL1
  hsa04640                                        Hematopoietic cell lineage                0.0200                1.697467           CD1B//CD5//CD8A//CD9
  hsa04970                                        Salivary secretion, *Homo sapiens*        0.0216                1.665411           ADRB2//CST5//KCNN4//NOS1
  hsa00670                                        One carbon pool by folate                 0.0229                1.639815           ATIC//MTFMT
  hsa04977                                        Vitamin digestion and absorption          0.0322                1.490856           SLC19A2//SLC23A1
                                                                                                                                     
  *Hypermethylated diabetes*versus*control*                                                                                          
  hsa00910                                        Nitrogen metabolism                       0.0015                2.818773           CA13//CA5B//CA9//CPS1//GLU
  D2                                                                                                                                 
  APLN//CHRNA1//CHRNA5//CH                                                                                                           
  RNB3//CNR1//EDN1//EDNRB//                                                                                                          
  FSHB//GABRA6//GABRG2//GA                                                                                                           
  BRR1//GCG//GHR//GPR156//G                                                                                                          
  RIA1//GRM4//HCRTR2//LGR4//                                                                                                         
  NMUR2//NPFF//NPY1R//P2RX6                                                                                                          
  hsa04080                                        Neuroactive ligand-receptor interaction   0.0207                1.683002           //P2RY14//PLG//RXFP1//TAC4
  hsa00524                                        Butirosin and neomycin biosynthesis       0.0254                1.594577           GCK//HK2
  Glycosaminoglycan biosynthesis, heparan         EXT1//EXTL2//HS3ST5//XYLT                                                          
  hsa00534                                        Sulfate/heparin                           0.0361                1.441751           1
  CACNB2//EDN1//IGF1//ITGA1//                                                                                                        
  ITGB1//MYH6//PRKAG2//PRK                                                                                                           
  hsa05410                                        Hypertrophic cardiomyopathy (HCM)         0.0362                1.441099           AG3//TPM1
  hsa00750                                        Vitamin B6 metabolism                     0.0368                1.433896           PDXP//PSAT1
  hsa04950                                        Maturity onset diabetes of the young      0.0413                1.384024           GCK//HNF1A//NR5A2//PDX1
                                                                                                                                     
  *Hypomethylated diabetes*versus*prediabetes*                                                                                       
  hsa00770                                        Pantothenate and CoA biosynthesis         0.0137                1.86211            COASY//PANK2
  hsa04640                                        Hematopoietic cell lineage                0.0141                1.850323           CD14//CD1A//CD1B//CD3E
  hsa00590                                        Arachidonic acid metabolism               0.0304                1.516647           CYP2E1//GGT1//PLA2G12A
  hsa03320                                        PPAR signaling pathway                    0.0369                1.433374           ACSL4//NR1H3//PCK2
  hsa00591                                        Linoleic acid metabolism                  0.0378                1.42268            CYP2E1//PLA2G12A
                                                                                                                                     
  *Hypermethylated diabetes*versus*prediabetes*                                                                                      
  hsa05410                                        Hypertrophic cardiomyopathy (HCM)         0.0063                2.201901           CACNA1S//DMD//ITGA4//MY
  H6//PRKAB2//PRKAG3//TGFB3                                                                                                          
  //TNF//TNNI3//TPM4                                                                                                                 
  ACVR1B//CCR6//CCR8//CX3C                                                                                                           
  R1//CXCL1//CXCL9//EDAR//G                                                                                                          
  HR//IFNA2//IFNA21//IL18RAP//                                                                                                       
  IL3//IL3RA//IL4R//IL9//TGFB3//                                                                                                     
  TNF//TNFRSF10D//TNFRSF14//                                                                                                         
  hsa04060                                        Cytokine-cytokine receptor interaction    0.0085                2.071022           TNFRSF9//TNFSF18//TNFSF8
  hsa03060                                        Protein export                            0.0210                1.678045           SEC61G//SRP9//SRPR//SRPRB
  ADCY4//CACNA1S//DMD//ITG                                                                                                           
  A4//MYH6//TGFB3//TNF//TNNI                                                                                                         
  hsa05414                                        Dilated cardiomyopathy                    0.0251                1.600573           3//TPM4
  ADCY4//ANAPC11//ATF1//ATF                                                                                                          
  3//CCNB2//CREM//HLA-                                                                                                               
  A//HLA-                                                                                                                            
  E//IKBKB//KRAS//MAD2L1//M                                                                                                          
  RAS//MSX2//NFYB//TGFB3//T                                                                                                          
  hsa05166                                        HTLV-I infection                          0.0382                1.418455           LN2//TNF//WNT16//WNT5B
  ACSL6//IKBKB//PRKAB2//PRK                                                                                                          
  hsa04920                                        Adipocytokine signaling pathway           0.0455                1.342336           AG3//PTPN11//SOCS3//TNF
                                                                                                                                     
  *Hypomethylated prediabetes*versus*control*                                                                                        
  hsa00590                                        Arachidonic acid metabolism               0.0026                2.593265           CYP4F3//CYP4F8//PLA2G2C//P
  LA2G4E                                                                                                                             
  hsa00592                                        Alpha-linolenic acid metabolism           0.0211                1.676649           PLA2G2C//PLA2G4E
  hsa00591                                        Linoleic acid metabolism                  0.0278                1.555232           PLA2G2C//PLA2G4E
  MYLK3//PLA2G2C//PLA2G4E//                                                                                                          
  hsa04270                                        Vascular smooth muscle contraction        0.0301                1.521206           RAMP3
  hsa04350                                        TGF-beta signaling pathway                0.0352                1.453226           LEFTY2//SP1//TGFB3
                                                                                                                                     
  *Hypermethylated prediabetes*versus*control*                                                                                       
  hsa05202                                        Transcriptional misregulation in cancer   0.0190                1.720526           CCNT1//ELK4//EYA1//RARA
  hsa05221                                        Acute myeloid leukemia                    0.0425                1.371986           CHUK//RARA

[^1]: Academic Editor: Marco Bugliani
